1. Home
  2. WINA vs NUVB Comparison

WINA vs NUVB Comparison

Compare WINA & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Winmark Corporation

WINA

Winmark Corporation

HOLD

Current Price

$426.96

Market Cap

1.5B

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$8.62

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WINA
NUVB
Founded
1988
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
2.4B
IPO Year
1993
N/A

Fundamental Metrics

Financial Performance
Metric
WINA
NUVB
Price
$426.96
$8.62
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$9.63
AVG Volume (30 Days)
84.2K
10.2M
Earning Date
10-15-2025
11-03-2025
Dividend Yield
2.66%
N/A
EPS Growth
2.56
N/A
EPS
11.21
N/A
Revenue
$84,517,400.00
$26,748,000.00
Revenue This Year
$7.05
$283.17
Revenue Next Year
$3.60
$340.98
P/E Ratio
$38.01
N/A
Revenue Growth
3.35
1137.19
52 Week Low
$295.79
$1.54
52 Week High
$527.37
$8.70

Technical Indicators

Market Signals
Indicator
WINA
NUVB
Relative Strength Index (RSI) 51.25 76.08
Support Level $405.86 $7.46
Resistance Level $432.21 $8.24
Average True Range (ATR) 15.68 0.62
MACD 2.91 0.13
Stochastic Oscillator 68.18 97.20

Price Performance

Historical Comparison
WINA
NUVB

About WINA Winmark Corporation

Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: